HPC Offered for PRESERVE Expansion

Condition(s) studied

Investigational drug(s) / intervention(s)

Bone Marrow Transplant with Ossium's HPC, Marrow (bone marrow recovered from deceased organ and tissue donors): The HOPE Program does not include any investigational drugs. The medicines and procedures in this program are standard of care for a transplant. Bone marrow cells from a deceased organ and tissue donor for use in your transplant is the only product offered to you by Ossium Health.

Study summary

Ossium recognizes that not all patients who could benefit from Ossium's HPC, Marrow can access the PRESERVE trial for logistical or eligibility reasons. The HOPE program is expanded access program to serve these patients by providing our bone marrow product

Eligibility

Primary outcome measure(s)

• Neutrophil engraftment — 28 days
  1\. To determine cumulative incidences of neutrophil engraftment (ANC ≥500/µL for 3 consecutive values)

Trial sites (4)

More Ossium Health, Inc. trials in the USA